Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Ascendis Pharma A (ASND) over the last 11 years, with Q3 2025 value amounting to 2976.26%.

  • Ascendis Pharma A's Return on Capital Employed rose 29801500.0% to 2976.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 2976.26%, marking a year-over-year increase of 29801500.0%. This contributed to the annual value of 3.02% for FY2024, which is 6600.0% down from last year.
  • Ascendis Pharma A's Return on Capital Employed amounted to 2976.26% in Q3 2025, which was up 29801500.0% from 3537.93% recorded in Q2 2025.
  • Ascendis Pharma A's Return on Capital Employed's 5-year high stood at 3537.93% during Q2 2025, with a 5-year trough of 32.5% in Q1 2024.
  • For the 5-year period, Ascendis Pharma A's Return on Capital Employed averaged around 507.04%, with its median value being 0.47% (2022).
  • Its Return on Capital Employed has fluctuated over the past 5 years, first crashed by -318100bps in 2024, then skyrocketed by 35323600bps in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Return on Capital Employed stood at 0.31% in 2021, then crashed by -89bps to 0.58% in 2022, then crashed by -572bps to 3.88% in 2023, then skyrocketed by 40488bps to 1568.91% in 2024, then surged by 90bps to 2976.26% in 2025.
  • Its Return on Capital Employed was 2976.26% in Q3 2025, compared to 3537.93% in Q2 2025 and 1591.07% in Q1 2025.